What is B. Riley’s Estimate for VRDN Q2 Earnings?

Viridian Therapeutics, Inc. (NASDAQ:VRDN) – Investment analysts at B. Riley issued their Q2 2025 EPS estimates for Viridian Therapeutics in a research report issued on Monday, March 3rd. B. Riley analyst K. Patel forecasts that the company will post earnings of ($1.14) per share for the quarter. The consensus estimate for Viridian Therapeutics’ current full-year earnings is ($4.03) per share.

Viridian Therapeutics (NASDAQ:VRDN) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.81) EPS for the quarter, beating analysts’ consensus estimates of ($1.05) by $0.24. The company had revenue of $0.07 million for the quarter, compared to analyst estimates of $0.05 million. Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%.

A number of other research analysts have also commented on VRDN. Needham & Company LLC restated a “buy” rating and issued a $38.00 price objective on shares of Viridian Therapeutics in a research note on Tuesday, January 7th. TD Cowen began coverage on shares of Viridian Therapeutics in a research note on Monday, November 25th. They set a “buy” rating on the stock. Wells Fargo & Company reiterated an “equal weight” rating and set a $27.00 price target (down from $37.00) on shares of Viridian Therapeutics in a research note on Thursday, December 19th. HC Wainwright reiterated a “buy” rating and set a $34.00 price target on shares of Viridian Therapeutics in a research note on Monday, December 16th. Finally, Royal Bank of Canada boosted their price target on shares of Viridian Therapeutics from $44.00 to $47.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 17th. Three research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $35.70.

Viridian Therapeutics Trading Up 5.7 %

NASDAQ VRDN opened at $15.23 on Tuesday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 18.55 and a current ratio of 18.55. The firm has a market cap of $1.21 billion, a PE ratio of -3.53 and a beta of 1.32. Viridian Therapeutics has a one year low of $11.40 and a one year high of $27.20. The firm’s fifty day moving average is $18.02 and its two-hundred day moving average is $19.70.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in VRDN. R Squared Ltd acquired a new position in Viridian Therapeutics during the fourth quarter worth about $26,000. Foresite Capital Management VI LLC purchased a new stake in shares of Viridian Therapeutics in the fourth quarter valued at about $38,000. AlphaQuest LLC lifted its holdings in shares of Viridian Therapeutics by 119.0% in the fourth quarter. AlphaQuest LLC now owns 2,795 shares of the company’s stock valued at $54,000 after purchasing an additional 1,519 shares in the last quarter. Summit Investment Advisors Inc. lifted its holdings in shares of Viridian Therapeutics by 24.7% in the fourth quarter. Summit Investment Advisors Inc. now owns 7,646 shares of the company’s stock valued at $147,000 after purchasing an additional 1,516 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Viridian Therapeutics in the third quarter valued at about $149,000.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.